Lilly Deepens Oncology Pipeline with $1.4B Point Biopharma Purchase
Eli Lilly on Tuesday continued its buying spree with a $1.4 billion acquisition of the radiopharma company’s pipeline of clinical and preclinical radioligand therapies.
The Home of the Life Sciences Industry
Takeda Pulls Lung Cancer Drug After Confirmatory Trial Misses Primary Endpoint
The Japanese pharma is voluntarily withdrawing its lung cancer drug mobocertinib, marketed as Exkivity, from U.S. and global markets after it missed the mark in a Phase III confirmatory trial.
More Top Stories
- Biopharma Layoff Tracker 2023: Syros, PTC, Galecto and More Cut Staff
- FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing...
- Federal Judge Denies Request to Block Medicare Drug Price Negotiati...
- Lexeo, Abivax File for IPOs on Nasdaq Amid Industry-Wide Drought
- Structure Therapeutics’ Weight Loss Candidate Gets Phase I Win, Sto...
